461 related articles for article (PubMed ID: 34632844)
1. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
[TBL] [Abstract][Full Text] [Related]
2. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
[TBL] [Abstract][Full Text] [Related]
3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
4. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
Karthik K; Senthilkumar TMA; Udhayavel S; Raj GD
Hum Vaccin Immunother; 2020 Dec; 16(12):3055-3060. PubMed ID: 32845733
[TBL] [Abstract][Full Text] [Related]
5. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
Ricke DO
Front Immunol; 2021; 12():640093. PubMed ID: 33717193
[TBL] [Abstract][Full Text] [Related]
6. Immunopathogenesis and immunobiology of SARS-CoV-2.
Rabaan AA; Al-Ahmed SH; Al Mutair A; Alhumaid S; Sule AA; Tirupathi R; Fawzy M; Muhammad J; Khan A; Hasan A; Shrestha DB; Sah R; Dhawan M; Tiwari R; Bilal M; Ahmad T; Dhama K
Infez Med; 2021 Jun; 29(2):167-180. PubMed ID: 34061781
[TBL] [Abstract][Full Text] [Related]
7. The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production.
Shimizu J; Sasaki T; Yamanaka A; Ichihara Y; Koketsu R; Samune Y; Cruz P; Sato K; Tanga N; Yoshimura Y; Murakami A; Yamada M; Itoi K; Nakayama EE; Miyazaki K; Shioda T
Sci Rep; 2021 Dec; 11(1):23713. PubMed ID: 34887501
[TBL] [Abstract][Full Text] [Related]
8. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH
J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
10. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV
Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356
[TBL] [Abstract][Full Text] [Related]
11. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
12. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
[TBL] [Abstract][Full Text] [Related]
13. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.
Coish JM; MacNeil AJ
Microbes Infect; 2020 Oct; 22(9):405-406. PubMed ID: 32590062
[TBL] [Abstract][Full Text] [Related]
14. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
15. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: Significance of antibodies.
Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
[TBL] [Abstract][Full Text] [Related]
18. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.
Lee E; Oh JE
Mol Cells; 2021 Jun; 44(6):392-400. PubMed ID: 34059562
[TBL] [Abstract][Full Text] [Related]
19. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies.
Varghese PM; Tsolaki AG; Yasmin H; Shastri A; Ferluga J; Vatish M; Madan T; Kishore U
Immunobiology; 2020 Nov; 225(6):152008. PubMed ID: 33130519
[TBL] [Abstract][Full Text] [Related]
20. Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.
Harapan H; Ryan M; Yohan B; Abidin RS; Nainu F; Rakib A; Jahan I; Emran TB; Ullah I; Panta K; Dhama K; Sasmono RT
Rev Med Virol; 2021 Mar; 31(2):e2161. PubMed ID: 32946149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
